Nikolas Sofronis, Non-executive Chairman
Nikolas Sofronis, having graduated from the Athens Bar, is a lawyer by training. For the past 15 years, he has worked for numerous high profile asset management organisations. He focuses primarily in the biopharmaceuticals area whilst working for HSBC, Credit Lyonnais, Republic Bank of New York, and others.

Robert Morrisson Atwater, Chief Executive Officer
Robert Morrisson Atwater's career to date has spanned 15 years working in the bio-pharmaceutical industry, as well as financial services. Robert joins Cyprotex from San Francisco-based Thalassa Capital Management LLC, an asset management firm which he co-founded which concentrates on bio-pharmaceutical opportunities worldwide. Prior to Thalassa, Robert worked for a number of years in business development Europe and Asia for BioChem Pharma, which was subsequently acquired by Shire Pharmaceuticals Group plc. Robert has also worked for a number of prominent financial services companies. He studied at L'Universite de Neuchatel in Switzerland and is a graduate of the University of Massachusetts at Amherst.

Martial Lacroix, Non-executive Director
Martial Lacroix is the Vice President of GeneChem, a Montreal-based venture capital group with close to Canadian $250 million under management and investments in 31 companies located in Canada, the U.S.A. and the UK. Dr Lacroix was a co-founder of BioChem Pharma Inc. and previously held a number of positions with BioChem ImmunoSystems Inc., including Director, Research and Development and Director, Quality Control. Between 1981 and 1986, Dr. Lacroix was a Professor in the Department of Virology at Institut Armand-Frappier. Dr. Lacroix received a B.Sc. and a M.Sc. in biochemistry from University of Montreal and a Ph.D. from the University of Toronto. He has authored 33 scientific publications and holds eight issued patents. Currently Dr. Lacroix is a Director on the Board of seven privately held companies.

Minhaz Manji, Non-executive Director
Minhaz Manji is the Managing Director of Monteacute House Limited which builds limited service hotels under the name of Express by Holiday Inn (a franchise) of InterContinental Hotels Group. The company has a development agreement to build 15 hotels. Minhaz currently serves as the elected Chairman of Express Owners in the UK, currently numbering 80 hotels - an investment of over £600m. He also serves as a director on the advisory board of the newly formed InterContinental Group and serves on the Ethnic Minority Board of HH Prince Charles Youth Business Trust.

David Evans, Non-executive Director
David is a member of the intellectual property group at Genentech, Inc., one of the world's leading biotherapeutics companies. David has worked with cutting edge biopharmaceutical companies for the past 13 years, including BioChem Pharma, Allelix Biopharmaceuticals which was acquired by NPS Pharmaceuticals, and currently Genentech, Inc. of South San Francisco. David holds a Bachelor of Science degree from the University of Toronto in chemistry and biology and began his career in intellectual property at the Canadian Patent Office in 1991.

Russell Gibbs, Chief Financial Officer
Russell Gibbs experience has been gathered from over 20 years working in the international capital markets. His roles have ranged through asset valuation, company analysis and competitive assessment, through to restructuring, refinancing and new listing both in the bond, debt and equity markets. Russell worked for a range of major financial services companies, including UBS, Paribas and NatWest, during which time a focus on smaller technology and biotech investments familiarised him with running of such companies. He studied at Worcester Polytechnic Institute in Mass. USA and is a technology graduate from City University, London.